We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IDEX (IEX) Q2 Earnings Top Estimates, Sales Miss, '24 View Down
Read MoreHide Full Article
IDEX Corporation’s (IEX - Free Report) second-quarter 2024 adjusted earnings of $2.06 per share surpassed the Zacks Consensus Estimate of $2.04. The bottom line decreased approximately 6% from the year-ago quarter’s earnings of $2.18 per share. However, it exceeded management’s projection of $2.00-$2.05 per share.
Revenue Details
IDEX’s net sales of $807.2 million missed the Zacks Consensus Estimate of $831 million. The top line also decreased 5% year over year. Organic sales decreased 4% year over year. Foreign currency translation had a negative impact on sales by 1%.
IEX reports net sales under three business segments, the results of which are discussed below:
Net sales from the Fluid & Metering Technologies segment totaled $319.4 million, down 2% year over year. Our estimate for segmental net sales was $327 million. While organic sales were flat year over, acquisition/divestitures and foreign currency translation each had a negative impact of 1% on sales.
Net sales from the Health & Science Technologies segment totaled $303.8 million, indicating a year-over-year decline of 11%. Our estimate for segmental net sales was $321 million. Organic sales declined 11% year over year.
Net sales from the Fire & Safety/Diversified Products segment totaled $185.4 million, which increased marginally year over year. Our estimate for segmental net sales was $185 million. Organic sales increased 1% on a year-over-year basis while foreign currency translation hurt sales by 1%.
IDEX Corporation Price, Consensus and EPS Surprise
IDEX’s cost of sales decreased 5.9% year over year to $440.4 million. The gross profit was $366.8 million, down 3% year over year. The gross margin was 45.4% compared with 44.7% in the year-ago quarter.
Selling, general and administrative expenses increased 4.9% year over year to $182.8 million. Adjusted EBITDA decreased 6.9% year over year to $224.2 million. The adjusted EBITDA margin decreased 60 bps year over year to 27.8%.
The operating income was $182.7 million, down 8.7% year over year. The operating margin was 22.6%, down 100 bps year over year. Interest expenses (net) decreased 39.1% year over year to $8.1 million.
Balance Sheet and Cash Flow
While exiting the second quarter, IDEX’s cash and cash equivalents were $700.7 million compared with $534.3 million at the end of fourth-quarter 2023. Long-term borrowings (net) were $1.30 billion compared with $1.33 billion at the end of fourth-quarter 2023.
In the first six months of 2024, IDEX generated net cash of $290.2 million from operating activities, up 0.4% from the year-ago period. Capital expenditures were $35.9 million compared with $48.2 million in the first six months of 2023. In the same period, free cash flow was $254.3 million, up 5.5% year over year.
Idex paid out dividends totaling $100.7 million in the first six months of 2024, up 7.2% year over year.
Outlook
For the third quarter, IDEX anticipates adjusted earnings to be in the band of $1.85-$1.90 per share.
On a GAAP basis, IEX predicts earnings to be in the range of $1.61-$1.66 per share and a 0-1% increase in organic sales from the respective year-ago readings.
For 2024, IDEX anticipates adjusted earnings to be $7.80-$7.90 per share, down from the earlier projected range of $8.15 - $8.45. The figure indicates a decrease from earnings of $8.22 per share reported in 2023. On a GAAP basis, earnings are predicted to be $6.85-$6.95 per share, down from the earlier guided range of $7.13-$7.43.
Organic sales are predicted to decline 1-2% compared with the 0-2% decline guided earlier.
Zacks Rank & Stocks to Consider
IDEX currently carries a Zacks Rank #4 (Sell). Some better-ranked companies from the Industrial Products sector have been discussed below:
It has a trailing four-quarter average earnings surprise of 18%.
The Zacks Consensus Estimate for KAI’s 2024 earnings has increased 0.2% in the past 60 days.
Flowserve Corporation (FLS - Free Report) currently carries a Zacks Rank #2 (Buy). FLS delivered a trailing four-quarter average earnings surprise of 18.2%.
In the past 60 days, the consensus estimate for Flowserve’s 2024 earnings has increased 0.8%.
Emerson Electric Co. (EMR - Free Report) presently carries a Zacks Rank of 2. The company delivered a trailing four-quarter average earnings surprise of 10.7%.
In the past 60 days, the Zacks Consensus Estimate for EMR’s 2024 earnings has increased 0.4%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
IDEX (IEX) Q2 Earnings Top Estimates, Sales Miss, '24 View Down
IDEX Corporation’s (IEX - Free Report) second-quarter 2024 adjusted earnings of $2.06 per share surpassed the Zacks Consensus Estimate of $2.04. The bottom line decreased approximately 6% from the year-ago quarter’s earnings of $2.18 per share. However, it exceeded management’s projection of $2.00-$2.05 per share.
Revenue Details
IDEX’s net sales of $807.2 million missed the Zacks Consensus Estimate of $831 million. The top line also decreased 5% year over year. Organic sales decreased 4% year over year. Foreign currency translation had a negative impact on sales by 1%.
IEX reports net sales under three business segments, the results of which are discussed below:
Net sales from the Fluid & Metering Technologies segment totaled $319.4 million, down 2% year over year. Our estimate for segmental net sales was $327 million. While organic sales were flat year over, acquisition/divestitures and foreign currency translation each had a negative impact of 1% on sales.
Net sales from the Health & Science Technologies segment totaled $303.8 million, indicating a year-over-year decline of 11%. Our estimate for segmental net sales was $321 million. Organic sales declined 11% year over year.
Net sales from the Fire & Safety/Diversified Products segment totaled $185.4 million, which increased marginally year over year. Our estimate for segmental net sales was $185 million. Organic sales increased 1% on a year-over-year basis while foreign currency translation hurt sales by 1%.
IDEX Corporation Price, Consensus and EPS Surprise
IDEX Corporation price-consensus-eps-surprise-chart | IDEX Corporation Quote
Margin Profile
IDEX’s cost of sales decreased 5.9% year over year to $440.4 million. The gross profit was $366.8 million, down 3% year over year. The gross margin was 45.4% compared with 44.7% in the year-ago quarter.
Selling, general and administrative expenses increased 4.9% year over year to $182.8 million. Adjusted EBITDA decreased 6.9% year over year to $224.2 million. The adjusted EBITDA margin decreased 60 bps year over year to 27.8%.
The operating income was $182.7 million, down 8.7% year over year. The operating margin was 22.6%, down 100 bps year over year. Interest expenses (net) decreased 39.1% year over year to $8.1 million.
Balance Sheet and Cash Flow
While exiting the second quarter, IDEX’s cash and cash equivalents were $700.7 million compared with $534.3 million at the end of fourth-quarter 2023. Long-term borrowings (net) were $1.30 billion compared with $1.33 billion at the end of fourth-quarter 2023.
In the first six months of 2024, IDEX generated net cash of $290.2 million from operating activities, up 0.4% from the year-ago period. Capital expenditures were $35.9 million compared with $48.2 million in the first six months of 2023. In the same period, free cash flow was $254.3 million, up 5.5% year over year.
Idex paid out dividends totaling $100.7 million in the first six months of 2024, up 7.2% year over year.
Outlook
For the third quarter, IDEX anticipates adjusted earnings to be in the band of $1.85-$1.90 per share.
On a GAAP basis, IEX predicts earnings to be in the range of $1.61-$1.66 per share and a 0-1% increase in organic sales from the respective year-ago readings.
For 2024, IDEX anticipates adjusted earnings to be $7.80-$7.90 per share, down from the earlier projected range of $8.15 - $8.45. The figure indicates a decrease from earnings of $8.22 per share reported in 2023. On a GAAP basis, earnings are predicted to be $6.85-$6.95 per share, down from the earlier guided range of $7.13-$7.43.
Organic sales are predicted to decline 1-2% compared with the 0-2% decline guided earlier.
Zacks Rank & Stocks to Consider
IDEX currently carries a Zacks Rank #4 (Sell). Some better-ranked companies from the Industrial Products sector have been discussed below:
Kadant Inc. (KAI - Free Report) presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
It has a trailing four-quarter average earnings surprise of 18%.
The Zacks Consensus Estimate for KAI’s 2024 earnings has increased 0.2% in the past 60 days.
Flowserve Corporation (FLS - Free Report) currently carries a Zacks Rank #2 (Buy). FLS delivered a trailing four-quarter average earnings surprise of 18.2%.
In the past 60 days, the consensus estimate for Flowserve’s 2024 earnings has increased 0.8%.
Emerson Electric Co. (EMR - Free Report) presently carries a Zacks Rank of 2. The company delivered a trailing four-quarter average earnings surprise of 10.7%.
In the past 60 days, the Zacks Consensus Estimate for EMR’s 2024 earnings has increased 0.4%.